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Vasodilator-Stimulated Phosphoprotein
(VASP)-dependent and -independent
pathways regulate thrombin-induced
activation of Rap1b in platelets
Peter M. Benz1, Hebatullah Laban1, Joana Zink1, Lea Günther1, Ulrich Walter2, Stepan Gambaryan3,4
and Karim Dib5*
Abstract
Background: Vasodilator-Stimulated Phosphoprotein (VASP) is involved in the inhibition of agonist-induced platelet
aggregation by cyclic nucleotides and the adhesion of platelets to the vascular wall. αIIbβ3 is the main integrin responsible
for platelet activation and Rap1b plays a key role in integrin signalling. We investigated whether VASP is involved in the
regulation of Rap1b in platelets since VASP-null platelets exhibit augmented adhesion to endothelial cells in vivo.
Methods: Washed platelets from wild type and VASP-deficient mice were stimulated with thrombin, the purinergic
receptors agonist ADP, or the thromboxane A2 receptor agonist U46619 and Rap1b activation was measured using the
GST-RalGDS-RBD binding assay. Interaction of VASP and Crkl was investigated by co-immunoprecipitation, confocal
microscopy, and pull-down assays using Crkl domains expressed as GST-fusion proteins.
Results: Surprisingly, we found that activation of Rap1b in response to thrombin, ADP, or U46619 was significantly
reduced in platelets from VASP-null mice compared to platelets from wild type mice. However, inhibition of thrombin-
induced activation of Rap1b by nitric oxide (NO) was similar in platelets from wild type and VASP-null mice indicating
that the NO/cGMP/PKG pathway controls inhibition of Rap1b independently from VASP. To understand how VASP
regulated Rap1b, we investigated association between VASP and the Crk-like protein (Crkl), an adapter protein which
activates the Rap1b guanine nucleotide exchange factor C3G. We demonstrated the formation of a Crkl/VASP complex
by showing that: 1) Crkl co-immunoprecipitated VASP from platelet lysates; 2) Crkl and VASP dynamically co-localized at
actin-rich protrusions reminiscent of focal adhesions, filopodia, and lamellipodia upon platelet spreading on fibronectin; 3)
recombinant VASP bound directly to the N-terminal SH3 domain of Crkl; 4) Protein Kinase A (PKA) -mediated VASP
phosphorylation on Ser157 abrogated the binding of Crkl.
Conclusions: We identified Crkl as a novel protein interacting with VASP in platelets. We propose that the C3G/Crkl/VASP
complex plays a role in the regulation of Rap1b and this explains, at least in part, the reduced agonist-induced activation
of Rap1b in VASP-null platelets. In addition, the fact that PKA-dependent VASP phosphorylation abrogated its interaction
with Crkl may provide, at least in part, a rationale for the PKA-dependent inhibition of Rap1b and platelet aggregation.
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Plain English summary
Platelets, or thrombocytes, are the second most common
kind of blood cells in the human body. Along with the
coagulation factors, the main function of platelets is to
stop bleeding by clumping and clotting blood vessel in-
juries (hemostasis). Hemostasis can be divided into three
parts: platelet binding to the injured vessel (adhesion),
platelet shape change and secretion of messengers (acti-
vation), and platelet bridging (aggregation). An import-
ant step in platelet function is the activation of the
platelet receptor integrin αIIbβ3, which is regulated by
the small GTPase Rap1b. In the present study, we inves-
tigated whether Vasodilator-Stimulated Phosphoprotein
(VASP) is involved in the regulation of Rap1b in plate-
lets. To address this question, we activated platelets
from wild-type and VASP-deficient mice and measured
Rap1b activity. We found that activation of Rap1b was
reduced in platelets from VASP-deficient mice. We iden-
tified a novel VASP binding partner in platelets, the
adapter protein Crkl, which is important for Rap1b acti-
vation. Furthermore, we found that the interaction of
Crkl and VASP is abrogated by PKA, which plays an im-
portant role in the inhibition of platelet function. To-
gether, we propose that the control of the interaction of
VASP and Crkl by PKA is important for Rap1b activa-
tion in platelets.
Background
The central event in platelet adhesion at sites of vascular
injury is the agonist-induced inside-out activation of
αIIbβ3 integrin [1], a process in which the small GTPase
Rap1b plays a key role [2]. Indeed, Rap1b is activated in
response to agonists [3] and platelets from Rap1b knock-
out mice exhibit defects in αIIbβ3 integrin-dependent
arterial thrombus formation [4]. Rap1b cycles between
an active GTP-bound and an inactive GDP-bound con-
formation. The GDP-GTP switch is brought about by
the guanine nucleotide exchange factors (GEFs). In
platelets, the GEF CalDAG-GEFI is critical for the rapid
activation of Rap1b. This process is triggered by the
binding of Ca2+ to its site on CalDAG-GEFI thus confer-
ring GEF activity towards Rap1b [5]. Our previous work
showed that phosphorylation of CalDAG-GEFI is a
critical mechanism by which PKA controls Rap1b-
dependent platelet aggregation [6]. CalDAG-GEFI has
been extensively studied in platelets in relation to Rap1b
activation, however, little attention has been paid to
C3G, which also plays a role in platelet clotting through
its ability to catalyse GTP-loading of Rap1b [7]. C3G is
activated by interacting, via its proline-rich domain, with
the SH3 domain of Crk adaptor proteins and its subse-
quent tyrosine phosphorylation [8, 9]. In platelets, the
dominant Crk protein is Crk-like (Crkl). It is abundant
and acts as an adapter for Wiskott-Aldrich syndrome
protein and the tyrosine kinase Syk [8, 9]. The subse-
quent hydrolysis of bound GTP to GDP on Rap1b is
catalyzed by GTPase-activating proteins (GAPs), and
terminates the interaction between Rap1b and effector
proteins controlling platelet functions. In platelets,
Rap1GAP2 exhibits strong GAP activity towards Rap1b
[10].
Circulating platelets are also continually exposed to in-
hibitory factors such as NO and prostacyclin (PGI2) de-
rived from the endothelium whose effects are mediated
through cGMP and cAMP, respectively [1]. It was shown
that PGI2 and NO inhibit platelet aggregation through
their ability to block Rap1b activation [11].
Whereas Rap1b controls activation of αIIbβ3 integrin,
VASP is involved in the inactivation of this integrin [12].
VASP belongs to the Ena/VASP protein family and is an
important regulator of cytoskeletal dynamics linking cyc-
lic nucleotide-dependent pathways to actin remodelling
[13]. Evidences for a negative role of VASP in the regula-
tion of integrins come from studies using platelets de-
rived from VASP knock out mice. It was shown that
cAMP- and cGMP-mediated inhibition of platelet aggre-
gation is significantly reduced in VASP-null platelets
[14] and VASP-null platelets exhibit augmented aggrega-
tion to endothelial cells in vivo [15]. How VASP nega-
tively controls platelet integrins is not known.
Since activation of αIIbβ3 integrin is dependent on
Rap1b, we hypothesized that VASP may be a negative
regulator of αIIbβ3 integrin through its ability to inhibit
Rap1b. To test this hypothesis, we compared activation
of Rap1b in platelets from VASP-null and wild type mice
in response to platelet agonists. We also investigated
whether VASP interacted with Crkl in order to under-
stand the mechanism by which VASP could regulate cyc-
lic nucleotide-mediated regulation of Rap1b and platelet
aggregation.
Methods
General reagents
Anti-VASP (sc-46668), anti-Crkl (sc-319), and anti-
Rap1b (sc-65) Abs were obtained from Santa Cruz
Biotechnology; anti-CalDAG-GEFI and anti-Rap1GAP2
Abs were from ImmunoGlobe GmbH (Himmelstadt,
Germany); anti-VASP-pSer235 (clone 16C2) was from
nanoTools (Teningen, Germany). Alexa Fluor 633 phal-
loidin (Invitrogen) was used to visualize actin filaments.
The protease inhibitor cocktail was purchased from
Roche.
Plasmids encoding the GST-Crkl fusion proteins were
a generous gift of Dr. Stephan Feller (Martin-Luther-
University Halle-Wittenberg, Germany) and proteins
were purified on Glutathione-conjugated sepharose as
detailed previously [16]. Recombinant His6-tagged
human VASP was purified from E.coli cultures and
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VASP was phosphorylated by PKA in vitro as previously
described [16]. Protein purities and concentrations were
determined by Coomassie blue staining using bovine
serum albumin (BSA) as reference.
Rap1b pull-down assays
Platelets (2 × 108) were lysed with an ice cold buffer
composed of 50 mM Tris-HCl (pH 7.4), 1 % Triton X-
100, 100 mM NaCl, 10 mM MgCl2, 20 % glycerol, 1 mM
Na3VO4, and 1 mM pefabloc. The GST-RalGDS fusion
protein, coupled to glutathione-sepharose beads, was
used to pull down GTP-bound Rap1b as described [17].
The beads were subsequently re-suspended in 50 μl
Laemmli sample buffer supplemented with 3 μl of 1 M
DTT. The samples were subjected to 12 % SDS-PAGE,
and transferred to PVDF membranes. The membranes
were blocked in phosphate-buffered saline (PBS) supple-
mented with 0.2 % Tween 20 and 3 % milk, and then in-
cubated overnight at 4 °C with an anti-Rap1 Ab (1 μg/
ml dilution). After three washes with lysis buffer, the
membranes were subsequently incubated for 1 h with
goat peroxidase-conjugated anti-rabbit IgGs (1:10 000).
The blots were again washed and antibody binding was
visualised by enhanced chemiluminescence.
Immunoprecipitations and GST pull-down assays
For immunoprecipitation, human platelets (2 × 108)
were lysed in the following buffer: 40 mM Hepes-NaOH,
pH 7.5, 90 mM NaCl, 1 % Igepal CA-630, and a protease
inhibitor cocktail. Lysates were clarified by centrifuga-
tion for 10 min at 16,000 x g at 4 °C, and Crkl was sub-
jected to immunoprecipitation using either anti-Crkl
specific Abs or isotype control Abs, followed by incuba-
tion with protein G-conjugated sepharose beads. After
extensive washing with the lysis buffer, the precipitated
material was analyzed by Western blotting using anti-
Crkl or anti-VASP Abs.
For pull-down assays using GST-fusion proteins, hu-
man platelets (2 × 108) were either treated with a com-
bination of forskolin (FSK) (5 μM) and okadaic acid
(OA) (1 μM) for 20 min at 37 °C to stimulate PKA activ-
ity (+PKA) or left untreated (−PKA). Thereafter, cells
were lysed as described above. Clarified lysates were in-
cubated with 20 μg GST-Full-length-Crkl (GST-FL-Crkl)
or equimolar amounts of GST-Crkl-SH2, GST-Crkl-
SH3N, GST-Crkl-SH3C, GST alone (negative control),
or GST-Spec-SH3 (positive control) coupled to glutathi-
one sepharose beads. GST pull-down experiments with
recombinant VASP were performed as above, using
500 ng of in vitro PKA-phosphorylated or non-
phosphorylated His6-VASP and 5 μg GST-FL-Crkl or
equimolar amounts of the other fusion proteins in the
presence of 25 ng/μl BSA to block unspecific interac-
tions. After extensive washing of the pelleted glutathione
sepharose beads, precipitated material was analyzed by
Western blotting using anti-VASP Abs.
Confocal microscopy
Washed human platelets (9 × 106) were seeded on
fibronectin-coated (25 μg/ml) 8-well glass bottom μ-
slides (Ibidi) and fixed with 4 % formalin after 2, 5, 12,
and 30 min incubation at room temperature. Cells were
extensively washed with PBS, blocked/permeabilized
with 5 % normal donkey serum in PBS containing 0.2 %
Triton X-100, and incubated with 1:80 diluted primary
Abs in 0.1 % BSA in PBS containing 0.2 % Triton X-100.
After extensive washing, platelets were incubated with
Alexa Fluor 488/546 conjugated donkey anti-mouse or
donkey anti-rabbit Abs (Invitrogen), washed again, and
mounted with 50 % glycerol in PBS containing 5 %
DABCO (Sigma-Aldrich) as an anti-fading agent. Stained
sections were investigated using a confocal laser scan-
ning microscope (LSM 780, Zeiss) equipped with a 63-
fold oil immersion objective. Images were acquired and
prepared for presentation using the ZEN software (Carl
Zeiss, version 2.1, black, 64 bit).
Results
Agonist-induced Rap1b activation is reduced in VASP-null
platelets
Washed platelets from wild-type (WT) or VASP-
deficient mice (VASP KO) were stimulated with throm-
bin, the purinergic receptor agonist ADP, or the thromb-
oxane A2 receptor agonist U46619 and Rap1b activation
was measured by GST-RalGDS-RBD binding assay. We
have previously shown augmented basal Rap1a activity
in neutrophils from VASP-null mice [17]. To our sur-
prise, we observed that activation of Rap1b in response
to thrombin (0.01 U/ml, 30s), the purinergic receptor
agonist ADP (10 μM, 1 min), or the thromboxane A2 re-
ceptor agonist U46619 (1 μM, 1 min) was significantly
decreased in VASP-null platelets in comparison to wild
type platelets (Fig. 1a). The decrease of Rap1b activation
in VASP-null platelets (versus wild type platelets) was
1.9-fold with thrombin (n = 5, p < 0.05), 2.8-fold with
ADP (n = 3, p < 0.05) and 2.7-fold with U46619 (n = 3, p
< 0.05) (Figs. 1b-d). We excluded that impaired Rap1b
activation in VASP-null platelets was due to changes in
the expression levels of CalDAG-GEFI, the dominant
GEF expressed in platelets [5]. Indeed, genetic deletion
of VASP did not affect the level of CalDAG-GEFI ex-
pression (Fig. 1a, lower blot).
Translocation of CalDAG-GEFI and Rap1GAP2 is independent
of VASP
Activation of monomeric GTPases is associated with
their movement, together with their regulators (GEFs
and GAPs), from the cytosol to the membrane fraction.
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Fig. 1 Agonist-induced Rap1b activation is reduced in VASP-null platelets. a Platelets (2 x108) from wild type (WT) or VASP-null platelets (VASP
KO) were unstimulated (control) or stimulated with thrombin (0.01 U/ml, 30s), ADP (10 μM, 1 min), or U46619 (1 μM, 1 min) (non-aggregating
conditions). Thereafter, platelets were lysed and GST-RalGDS-RBD pull-down assays were performed as described in Methods. Proteins bound to
GST-RalGDS-RBD were separated by 12 % SDS-PAGE, transferred to PVDF membranes, which were subjected to immunoblotting with anti-Rap1b
Abs. The insets show representative Western Blots. Levels of Rap1b, VASP, or CalDAG-GEFI in the whole lysates used for the Rap1b pull-down
assays were measured by Western blot analysis using appropriate Abs. The diagrams (b-d) illustrate densitometric analysis of the relative activities
of Rap1b. Levels of Rap1b-GTP/total Rap1b in WT and VASP KO platelets stimulated with thrombin (b) (n = 5), ADP (c) (n = 3), or U46619 (d)
(n = 3) were quantified by densitometry analysis using ImageJ software. *P < 0.05
WT VASP KOWT VASP KO
Cytosol Membrane
Rap1b
CalDAG-GEFI
+ +- -
Thrombin
+ +- -
Thrombin
Rap1GAP2
Loading controls
Fig. 2 Translocation of CalDAG-GEFI and Rap1GAP2 is independent of VASP. Platelets from wild-type (WT) or VASP-deficient mice (VASP KO) stimulated or
not with thrombin (0.01 U/ml, 30s) were broken by sonication in detergent-free buffer. Lysates were spun at 100,000 g for 1 h. Cytosolic (supernatant) and
crude membrane fractions (pellet) were collected and re-suspended in Laemmli buffer. Proteins were separated by 12 % SDS-PAGE, transferred to PVDF
membranes, which were subjected to immunoblotting with one of the following Abs: anti-Rap1GAP2, anti-Rap1b or anti-CalDAG-GEFI. The Western blots
show the results of one representative experiment (out of three). Protein loading controls (Ponceau S red staining of the blots) are shown in the
bottom panels
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We next investigated whether VASP controlled the
movement of Rap1b, CalDAG-GEFI or Rap1GAP2, the
dominant GAP for Rap1b in platelets [10]. Stimulation
of wild type or VASP-null platelets with thrombin (0.01
U/ml, 30s) led to a similar reduction of Rap1b in the
cytosol, however, we could not detect augmented levels
of Rap1b in the membrane fraction (Fig. 2). This can be
explained by the fact that the majority of Rap1b (90 %)
is present in the inner face of the membrane in resting
platelets [18]. We observed similar movement of Rap1-
GAP2 from the cytosol to the membrane fraction in re-
sponse to thrombin in both wild type and VASP-null
platelets (Fig. 2). In contrast, we did not detect any
translocation of CalDAG-GEFI from the cytosol to the
membrane fraction in response to thrombin regardless
of VASP expression (Fig. 2). These experiments indicate
that impaired activation of Rap1b in response to throm-
bin in VASP-null platelets is not due to defects in the re-
distribution of Rap1b, Rap1GAP2, or CalDAG-GEFI
between cytosolic and membrane fractions.
NO-dependent inhibition of Rap1b is not impaired in
VASP-null platelets
In addition to activating factors, platelets circulating in
vivo are continuously exposed to inhibitory factors such
as endothelium-derived NO and prostacyclin [1]. Most, if
not all, inhibitory effects of NO on platelets are mediated
by the soluble guanylyl cyclase/cGMP/PKG pathway [19].
Interestingly, suppression by NO of platelet tethering and
adhesion to the injured vessel wall in vivo is less pro-
nounced in the absence of VASP [15], indicating that
phosphorylation of VASP by PKG may control inhibition
of Rap1b. To test this hypothesis, we pre-treated mouse
platelets with sodium nitroprusside (SNP), a NO-releasing
drug, which strongly induces PKG-mediated VASP phos-
phorylation at serine 235 (Fig. 3a, third blot from the top),
equivalent to serine 239 in human VASP, before stimula-
tion with thrombin. Although the overall Rap1b-GTP
levels were reduced in VASP-deficient platelets, we ob-
served a similar SNP-mediated inhibition of thrombin-
induced Rap1b activation in VASP-null and wild type
platelets (Fig. 3a and b).
Crkl and VASP dynamically interact in platelets
C3G is a GEF for Rap1b, which is activated through its
recruitment by the docking protein Crkl. In adherent
cells, VASP is localized to actin rich structures including
the integrin-based focal adhesions and membrane pro-
trusions such as filopodia, lamellipodia, and ruffles [13,
16, 20]. Crkl was also reported to localize to focal adhe-
sions in mouse embryonic fibroblasts and COS7 cells
[21, 22]. We asked whether VASP and Crkl could form
protein complexes in platelets. To experimentally ad-
dress this question, we immunoprecipitated Crkl from
platelet lysates and analyzed the precipitated material by
Western blot analysis using anti-VASP specific Abs. We
found that the anti-Crkl Abs, but not the isotype control
Abs, specifically precipitated VASP from platelet lysates,
indicating an interaction between VASP and Crkl in
living cells (Fig. 4a). We further confirmed such inter-
action between Crkl and VASP in other tissues and cells
b
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Fig. 3 NO-dependent inhibition of Rap1b activation is not impaired in VASP-null platelets. a Platelets (2 × 108) from WT mice (left panel) or VASP KO
mice (right panel) were pretreated for 2 min with SNP (1–5 μM) and then stimulated with thrombin (0.01 U/ml, 30s). Cells were lysed and the levels of
Rap1b-GTP/total Rap1b were measured as described in the legend to Fig. 1. PKG-mediated phosphorylation of VASP at serine 235 (pS235-VASP) and
levels of CalDAG-GEFI in whole lysates were measured using VASP phospho-specific or anti-CalDAG-GEFI Abs, respectively. The Western blots show the
results of one representative experiment (out of three). b Quantification of the percent inhibition by SNP (1–5 μM) of thrombin-induced activation of
Rap1b in both WT and VASP KO platelets. Please note that the blot in panel A (right) was more exposed than the blot in panel A (left)
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including PLB-985 cells differentiated into neutrophil-
like cells and mouse spleen (data not shown).
Crkl-VASP interaction was further analysed by con-
focal immunofluorescence microscopy in platelets
seeded on fibronectin-coated glass slides. To address the
localization of Crkl and VASP during the dynamic adhe-
sion and spreading of the platelets, cells were fixed 2, 5,
12, and 30 min after seeding and then processed for
staining using anti-Crkl and anti-VASP specific Abs as
well as fluorescent- conjugated phalloidin to stain actin
fibres (Fig. 4b). Two min after seeding, most platelets
still displayed a round morphology with some actin-rich
protrusions reminiscent of filopodia extensions. Actin,
VASP, and Crkl co-localized in these membrane protru-
sions (black arrows indicate filopodia-like protrusions)
as indicated by the yellow/orange (Crkl and VASP), cyan
(VASP and actin), or magenta colour (Crkl and actin) of
the merged images (Fig. 4b, lower panels). As a control,
we showed that no staining was observed when non-
relevant primary Abs were used (data not shown). Five
min after seeding, the morphology of the platelets had
changed dramatically and the cells displayed a jagged
shape with nascent lamellipodia-like extensions and
primitive focal adhesions (arrows in Fig. 4c indicate
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Fig. 4 Crkl and VASP dynamically interact in human platelets. (a) Lysates of human platelets were immunoprecipitated (IP) with Abs against Crkl or isotype
control antibodys (control) as described in Methods. Lysate, wash fraction (Wash), and precipitated material were analyzed by Western blotting with anti-VASP
(upper panel) or anti-Crkl Abs (lower panel), respectively. The arrows on the right hand side indicate the position of VASP and Crkl. One representative
experiment (out of three) is shown. B-E, Washed human platelets were seeded onto fibronectin-coated glass slides for 2 min (b), 5 min (c), 12 min (d),
or 30 min (e) before fixation and staining with anti-VASP-specific Abs (green), anti-Crkl-specific Abs (red) or with fluorescent conjugated phalloidin to
visualize actin fibers (blue). The top panels in each section show individual stainings; lower panels show co-localization staining of VASP and Crkl, VASP
and actin, and Crkl and actin. Black arrows, white arrowheads, and white arrows indicate filopodia-, focal adhesion-, and lamellipodia-like membrane
protrusions, respectively. All images have a dimension of 20 × 20 μm to better visualize platelet spreading, scale bar in B is 5 μm. In e´, magnified views
of the indicated areas in e are shown; scale bar 1 μm
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lamellipodia-like protrusions, arrowheads indicate the
proximal part of focal-adhesion-like structures). Crkl
and VASP co-localized with actin at the leading edge of
the lamellipodia and at the proximal end of the focal ad-
hesions (Fig. 4c). Twelve min after seeding, the platelets
were again not fully spread, however, we observed a pro-
nounced formation of more maturated lamellipodia and
focal adhesions. Again, Crkl and VASP co-localized at
the leading edge of lamellipodia and at the base of focal
adhesions (Fig. 4d). Thirty min after seeding, the cells
were almost fully spread and a continuous lamelli-
podium was observed surrounding the entire cells
(Fig. 4e). Magnified views of the lamellipodium revealed
that VASP was mostly concentrated at the distal part of
the leading edge, whereas the overlapping F-actin and
Crkl showed a broader distribution and extended more
proximally within the lamellipodium (Fig. 4e´). We con-
cluded that Crkl and VASP form complexes at sites of
high actin turnover, including focal adhesion-, filopodia-,
and lamellipodia-like protrusions in platelets.
The N-terminal SH3 domain of Crkl is involved in direct
VASP-Crkl interaction
The adapter protein Crkl is composed of a N-terminal
SH2 domain followed by two SH3 domains, SH3N and
SH3C, respectively [23]. We have previously shown that
the αII-Spectrin-SH3 domain directly binds to the
proline-rich region of VASP [16, 24]. Therefore, we hy-
pothesized that one or both of the Crkl SH3 domains
may be involved in direct interaction with VASP. To test
this hypothesis, we expressed and purified a series of
GST-Crkl fusion proteins comprising the full length pro-
tein (GST-FL-Crkl), the SH2 domain (including the
linker region between the SH2 and the SH3N domain;
GST-SH2-Crkl), or each of the SH3 domains, SH3N
(GST-SH3N-Crkl) or SH3C (GST-SH3C-Crkl). As nega-
tive and positive controls, we used GST alone or the
SH3 domain of αII-spectrin (GST-Spec-SH3), respect-
ively. These different constructs are described in detail
in Fig. 5a and b. When we incubated a platelet lysate
with equimolar amounts of the purified GST-fusion pro-
teins described in Fig. 5a, GST-FL-Crkl and the spectrin
SH3 domain bound to VASP, but not GST-SH2-Crkl,
GST-SH3N-Crkl, or GST-SH3C-Crkl (Fig. 5c). This re-
sult was unexpected because SH2 and SH3 domains are
known to normally fold independently of external cues.
This indicates that the Crkl-VASP interaction either re-
quires the entire 3D structure of the Crkl protein for
docking or alternatively that VASP and Crkl are bridged
together through a third, so far unknown protein. To
experimentally address this question, we repeated the
pull-down experiments with recombinant His6-VASP,
purified from E.coli. We found that GST-FL-Crkl and
GST-SH3N-Crkl efficiently precipitated recombinant
His6-VASP. We also observed a weak but distinct bind-
ing of VASP to the GST-SH2-Crkl fusion protein, but
interaction of VASP with GST-SH3C-Crkl was negli-
gible. Furthermore, we found that binding of His6-VASP
to GST-FL-Crkl, GST-SH3N-Crkl, and GST-Spec-SH3
was comparable (Fig. 5d). Together, this demonstrates
that VASP interacts directly with Crkl and suggests that
the SH3N domain of Crkl is involved in the binding.
PKA-mediated VASP phosphorylation abrogates
Crkl-VASP interaction
Signalling via PKA is important for maintaining platelets
in a resting state and it was shown that PKA activity
downregulates Rap1b-mediated integrin activation and
platelet aggregation, at least in part, through phosphoryl-
ation of CalDAG-GEFI [6]. Since VASP is the major
cytoskeletal-associated PKA substrate in platelets [25],
we investigated whether PKA-mediated VASP phosphor-
ylation regulates the interaction with Crkl. To test this
hypothesis, we incubated washed human platelets with a
combination of FSK and OA to stimulate PKA-
dependent VASP phosphorylation at Ser157 (pS157-
VASP) and used the stimulated and non-stimulated
platelet lysates for pull-down assays with GST-FL-Crkl.
Because PKA-mediated VASP phosphorylation at Ser157
induces an electrophoretic mobility shift of the protein
from 46 to 50 kDa in SDS-PAGE, VASP specific Abs can
be used to detect the phosphorylation event (Fig. 6b and
c) as shown previously by us [20]. As control, we again
used the SH3 domain of αII-spectrin, because we have
previously shown that its interaction with VASP is sensi-
tive to VASP Ser157 phosphorylation [16]. Strikingly, al-
though equal amounts of stimulated and non-stimulated
platelet lysates were used in the pull-down assays, only
non-phosphorylated VASP protein bound to GST-FL-
Crkl (Fig. 6b). We also performed pull-down assays with
recombinant VASP which had been phosphorylated or
not in vitro by PKA. Again only the non-phosphorylated
protein was precipitated by GST-FL-Crkl (Fig. 6c), dem-
onstrating that PKA-mediated VASP phosphorylation
abrogates Crkl-VASP complex formation. Thus, both
PKA-mediated phosphorylation of CalDAG-GEFI [6]
and phosphorylation of VASP may contribute to the
PKA-dependent inhibition of Rap1b in platelets.
Discussion
An important step in platelet adhesion, spreading, and
aggregation is the activation of the platelet integrin
αIIbβ3, which is regulated by Rap1b. In the present study,
we investigated whether VASP was involved in the regu-
lation of Rap1b in platelets. The rationale for this study
was that we have previously shown augmented basal
Rap1a activation in neutrophils from VASP-null mice
[17] and therefore we expected a similar increase in
Benz et al. Cell Communication and Signaling  (2016) 14:21 Page 7 of 12
GTP-bound Rap1b in platelets from VASP-deficient
mice. To our surprise, Rap1b activation in response to
thrombin, ADP, and U46619 was significantly decreased
in platelets derived from VASP-null mice as compared
to wild type littermates. We excluded that the observed
impaired activation of Rap1b in VASP-null platelets was
due to reduced expression level of CalDAG-GEFI or de-
fects in the translocation of Rap1b, CalDAG-GEFI, and
Rap1GAP2 from the cytosol to the membrane fraction
during platelet activation with thrombin. We next inves-
tigated whether the NO/cGMP/PKG pathway, which
negatively regulates Rap1b in platelets [11], was ampli-
fied in VASP-null platelets as this could explain de-
creased agonist-induced Rap1b activation in those
platelets. This was not the case. Indeed, NO-dependent
inhibition of Rap1b activation was similar in VASP-null
and wild type platelets. This result was unexpected be-
cause VASP is abundant in platelets and is the major
cytoskeletal-associated PKG substrate [25]. Thus, the an-
tithrombotic activity of NO [26] is due, at least in part,
to inhibition of Rap1b [11] but is not mediated through
phosphorylation of VASP. Therefore, we propose that
NO inhibits Rap1b independently of VASP via activa-
tion of GAPs, which accelerate the hydrolysis of GTP
and therefore terminate the activation of Rap1b. Ac-
cordingly, NO/cGMP/PKG-dependent phosphorylation
of Rap1GAP2 has been shown to increase the GTPase
activity of Rap1GAP2 [10].
Since VASP is not involved in the movement of the
regulators of Rap1b, and does not play a role in the NO/
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cGMP/PKG-dependent inhibitory pathway, we next in-
vestigated whether VASP was involved in an alternative
pathway of Rap1b regulation, in which a GEF different
from CalDAG-GEFI could be involved. In this regard,
Gutiérrez-Herrero and co-workers [7] have demon-
strated, by using transgenic mouse models that overex-
press C3G or C3GΔCat (a dominant negative mutant
that lacks catalytic activity), that C3G increases platelet
activation and aggregation both in vitro and in vivo
through its ability to catalyse GTP-loading of Rap1b.
C3G is a GEF for Rap1b which is activated through re-
cruitment by the docking protein Crkl [8]. Crkl, which is
abundant in platelets [9], contains two SH3 domains
(SH3N and SH3C) and one SH2 domain [8]. We dem-
onstrated that VASP is dynamically interacting with
Crkl. Our binding studies with platelet lysates and re-
combinant VASP protein demonstrated that the VASP-
Crkl interaction is direct and involves the Crkl SH3N
domain. By interacting with Crkl, VASP may transfer
this protein to the platelet cytoskeleton by means of
interaction with F- or G- actin [13] and this would ex-
plain, at least in part, association of Crkl with the cyto-
skeleton in platelets [9]. Accordingly, we did not find
Crkl in the membrane fraction of wild type or VASP-
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null platelets (data not shown) and we showed that Crkl
and VASP form complexes at sites of high actin turn-
over, including focal adhesion-, filopodia-, and
lamellipodia-like protrusions during platelet spreading.
Crkl has been shown to recruit tyrosine kinases, such as
Syk, present in the cytoskeleton of activated platelets [9].
Such recruitment of Crkl to actin-rich structures may be
important for phosphorylation of C3G bound to Crkl
and the subsequent activation of Rap1b.
We made novel findings regarding the domains of
VASP and Crkl involved in complex formation. We
found that recombinant His6-VASP, but not VASP
present in platelet lysates, bound to both the GST-
SH3N-Crkl domain and the GST-SH2-Crkl fusion pro-
tein (however weakly). The SH2 domain of Crkl binds to
phospho-tyrosine motifs [27], but we could not detect
tyrosine phosphorylation of VASP purified from E.coli
(data not shown). However, when we closely examined
the sequence of GST-SH2-Crkl, which also covers the
linker region between the SH2 domain and the SH3N
domain, we spotted a Y105PSPP motif (numbering in hu-
man Crkl) in the linker, which conforms to the consen-
sus binding motif of the VASP EVH1 domain (F/L/W/
Y)PxϕP (where ϕ is a hydrophobic residue) [28]. There-
fore, we propose that binding of the VASP EVH1 do-
main to the Crkl linker may support the interaction of
SH3N-Crkl with VASP. The lack of binding of VASP in
platelet lysates to SH3N-Crkl may be explained by the
fact that some proteins in platelet lysates compete with
VASP for binding SH3N-Crkl and have a better affinity
than VASP for this motif. Alternatively, because VASP
forms oligomers with itself, Mena or Evl [29, 30], VASP
oligomers interaction with Crkl may require not only
the SH3N domain of Crkl, but also other domains in-
cluding the SH3C domain and the linker region between
the SH2 domain and the SH3N domain. Future studies
will be aimed at testing this hypothesis.
SH3 domains are the most abundant protein recogni-
tion motifs, comprising an estimated 409 copies in the hu-
man proteosome alone [31], mostly found in signal
transduction and cytoskeletal proteins. SH3 domain-
mediated interactions are commonly found in processes
that require the rapid subcellular recruitment or inter-
change of proteins during initiation of signalling cascades
and cytoskeletal rearrangements [32]. Due to the insuffi-
cient inherent specificity in most SH3-mediated interac-
tions, additional mechanisms exist in vivo to generate
protein binding selectivity. These are temporal and cell-
type specific gene expression, combination of multiple
separate interactions between two binding partners, and
the cooperative assembly of multiprotein complexes. Most
common, however, is the compartmentalization of binding
partners and the regulation of their interaction by post-
translational modifications such as phosphorylation [32].
In the present study, we showed that the interaction be-
tween VASP and Crkl takes place in actin-rich structures
and is regulated by means of phosphorylation of VASP on
serine 157. Thus, PKA-mediated phosphorylation of VASP
abrogates the interaction with Crkl which may, at least in
part, provide a rationale for the PKA-dependent inhibition
of Rap1b activation and platelet aggregation. Serine157 is
the preferred PKA phosphorylation site in VASP. Notably,
this phosphorylation site is located in close proximity to
the proline-rich region of VASP, which interacts with SH3
domain containing proteins. We and others have previ-
ously shown that PKA-mediated phosphorylation of VASP
S157 abrogates binding of some SH3-domains of proteins,
whereas binding of other SH3 domains of other proteins
seemed to be independent of the phosphorylation status
[16]. In contrast to the PKA phosphorylation site (S157),
the preferred PKG phosphorylation site (S239) is not lo-
cated in proximity to the proline-rich region of VASP, but
in the EVH2 domain, adjacent to the G-actin binding
motif. We have previously shown that phosphorylation at
this site affects actin dynamics rather than (SH3-domain
mediated) protein-protein interactions and subcellular
protein targeting [20].
Platelets express five types of integrins: three β1 integ-
rins and the two β3 integrins αvβ3 and αIIbβ3 [33]. The β1
integrins mediate platelet adhesion to the matrix proteins
collagen, fibronectin, and laminin, whereas αvβ3 and αIIbβ3
bind vitronectin and the RGD motif of Von Willebrand
factor, respectively [33]. In fibroblasts, engagement of αvβ3
leads to PKA-dependent phosphorylation of VASP which
drives suppression of β1 integrin activation. This is
achieved through disruption of the interaction between
phosphorylated VASP and the Rap1-GTP-interacting
adaptor molecule (RIAM) [34]. Based on this finding, it is
plausible that absence of VASP in platelets may relieve the
inhibition exerted by αvβ3 on β1 integrins, thus explaining
the augmented adhesive capacities of VASP-null platelets
to injured blood vessels [15] since we excluded any aug-
mented agonist-induced activation of Rap1b. This implies
that Rap1b not only controls integrin inside-out signalling
but plays a complex role in the regulation of platelet func-
tions as shown by other investigators reporting Rap1b
control of αIIbβ3 outside-in signalling as well as secretion
of platelet granules [35].
In summary, we propose that the formation of a
ternary C3G/Crkl/VASP complex regulates, in parallel
with CalDAG-GEFI, Rap1b-dependent platelet activa-
tion and this may explain why agonist-induced
activation of Rap1b in VASP-null platelets is im-
paired. PKA-dependent phosphorylation of VASP on
serine residue 157 abrogated Crkl binding, which may
provide, at least in part, a rationale for the PKA-
dependent inhibition of Rap1b activation and platelet
aggregation.
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Conclusions
Crkl and VASP are dynamically interacting in actin-rich
domains during platelet spreading and the interaction
involves the N-terminal SH3 domain of Crkl. We
propose that Crkl-VASP complex formation is important
for C3G-dependent Rap1b activation in platelets. Con-
versely, Rap1b activation in VASP-null platelets is
reduced. The interaction between Crkl and VASP is reg-
ulated by PKA-mediated VASP phosphorylation. This
may, at least in part, explain the PKA-dependent inhib-
ition of Rap1b and platelet aggregation.
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